Gilead Sciences Inc. (GILD)财报预测 - Gilead Sciences Inc. (GILD)将于2024年4月25日发布第一季度财报[1] - 预计第一季度HIV销售额将下降10-12%[2] - Biktarvy和Descovy的销售额可能会受到影响[3] Liver Disease产品销售预测 - Liver Disease产品组合的销售可能会受到慢性乙型肝炎病毒和慢性肝炎三重病毒产品需求增加的推动[5] - Veklury销售额可能会出现较大波动[6] - Cell Therapy产品销售额可能会略有增加[7] 收购及产品线扩展 - Gilead最近以43亿美元收购了CymaBay Therapeutics, Inc.，并将其产品引入Gilead的产品线[13]

In the latest trading session, Gilead Sciences (GILD) closed at $66.16, marking a -1.15% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Elsewhere, the Dow gained 0.06%, while the tech-heavy Nasdaq lost 0.52%. The HIV and hepatitis C drugmaker's stock has dropped by 9.53% in the past month, falling short of the Medical sector's loss of 6.22% and the S&P 500's loss of 1.66%. The investment community will be closely monitoring the performance of G ...

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 25 ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this HIV and hepatitis C drugmaker have returned -7.5% over the past month versus the Zacks S&P 500 composite's -0.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 7.5% over this period. Now the key question is: Where could the stock be headed in th ...

Gilead Sciences (GILD) closed the most recent trading day at $69.94, moving +0.75% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.15%. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.32%. Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 7.83% over the past month. This has lagged the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65% in that time. Investors will be eagerly wa ...

With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential. While exercising caution is prudent, given valid underperformance reasons exist, comparing current metrics to historical peaks could reveal bargain stocks at 52-week lows. Understanding the drivers of underperformance provides insight into rebound likelihood. Since recovery duration may mirror price declines gi ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this HIV and hepatitis C drugmaker have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 3.2% over this period. Now the key question is: Where could the stock b ...

MicroStockHub April is the start of a new month and more importantly a new quarter. Every quarter I like to review strategy and performance in my portfolio and I also like to research and find new stocks to buy that could drive portfolio gains for the rest of the year. It is getting tough to find stocks that offer value right now (and are worth buying) because the market has experienced solid gains over the past couple of months and it now trades at or near record highs. However, I have found some really in ...

主要业务 - 吉利德科学公司的主要业务包括HIV和肿瘤药物，其中HIV产品销售额占据了公司销售额的相当大比例[4],[7] 肿瘤领域增长 - 公司在肿瘤领域取得了显著增长，肿瘤产品销售额同比增长37%，达到近30亿美元，占据了公司业务的双位数比例[4],[5] 新业务发展 - 吉利德科学公司在新业务领域也有所发展，计划2030年销售额的三分之一来自肿瘤业务，目前已有4项临床试验和近30亿美元的销售额[9],[10]

公司表现 - Gilead Sciences (GILD) 最近成为 Zacks.com 最受关注股票之一[1] - Gilead Sciences 的股价在过去一个月中上涨了 +1.9%，而 Zacks S&P 500 综合指数上涨了 +3.6%。Gilead 属于 Zacks 医疗 - 生物医学和遗传学行业，该行业在此期间下跌了 0.7%[2] - Gilead 预计本季度每股盈利为 $1.56，同比增长 +13.9%。当前财年的共识盈利预期为 $7.07，同比增长 +5.2%[5] - 下一个财年的共识盈利预期为 $7.50，同比增长 +6%[6] - Gilead 的股票评级为 Zacks Rank 3 (Hold)，这是基于盈利预期变化等因素的综合评级[7] 财务表现 - 公司的营收增长预测对于评估其财务健康至关重要[8] - Gilead 当前季度的共识销售预期为 $6.3 亿，同比下降 -0.8%。当前和下一个财年的销售预期分别为 $27.45 亿和 $28.13 亿，同比增长分别为 +1.2% 和 +2.5%[9] - Gilead 上一季度的营收为 $7.12 亿，同比下降 -3.7%。每股盈利为 $1.72，与去年同期的 $1.67 相比略有增长[10] - 与 Zacks 共识预期的 $7.08 亿相比，Gilead 的营收出现了 +0.51% 的惊喜。每股盈利的惊喜为 -2.27%[11] - 在过去四个季度中，Gilead 仅一次超过了每股盈利预期，但在这段时间内三次超过了共识营收预期[12] 估值评级 - 股票的估值对于投资决策至关重要，Zacks Value Style Score 给出了 Gilead 的 A 级评级，表明其相对同行公司交易时存在折价[16] 综合展望 - 总结来看，Gilead 的股票可能会在近期与整体市场表现一致[17]